Omeprazole
Proton Pump Inhibitors
Sold as Acid Reducer · LOSEC · LOSEC MUPS · HEARTBURN CONTROL
- Drug class
- Proton Pump Inhibitors
- Availability
- Prescription and OTC
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 170
- FDA reports (12 mo)
- 16,884
Overview
Plain-language summary, compiled from the cited regulatory records
Omeprazole is a medication belonging to the drug class of Proton Pump Inhibitors [1]. It is approved for the treatment of frequent heartburn, which is defined as heartburn occurring 2 or more days per week [1]. This medication is not intended for immediate relief of heartburn symptoms and may require 1 to 4 days to achieve its full effect [1].
Omeprazole is available under various brand names, including Acid Reducer [1]. In the past 12 months, there have been 16,884 adverse event reports associated with this active ingredient [2]. The most frequently reported adverse events include diarrhea, fatigue, nausea, off-label use, and headache [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 117 | May 29, 2026 |
| US United States | FDA | 35 | April 17, 2026 |
| CA Canada | Health Canada | 18 | May 13, 2026 |
GBUnited Kingdom· MHRA
117 products
Uses
Omeprazole gastro resistant tablets are indicated for:
Adults • Treatment of duodenal ulcers • Prevention of relapse of duodenal ulcers • Treatment of gastric ulcers • Prevention of relapse of gastric ulcers • In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic ulcer disease • Treatment of NSAID-associated gastric and duodenal ulcers • Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk • Treatment of reflux oesophagitis • Long-term management of patients with healed reflux oesophagitis • Treatment of symptomatic gastro-oesophageal reflux disease • Treatment of Zollinger-Ellison syndrome
How to take
USUnited States· FDA
35 products
Uses
Use(s) treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
How to take
CACanada· Health Canada
18 products
Uses
, functional dyspepsia); • Zollinger-Ellison syndrome (pathological hypersecretory condition); • eradication of Helicobacter pylori (H. pylori). *A working definition of dyspepsia would include the presence of epigastric pain/discomfort, with or without heartburn and regurgitation which may be accompanied by nausea, vomiting, bloating, belching, flatulence, early satiety or post-prandial fullness.
Symptoms may occur either during the day or throughout the night. JAMP-Omeprazole DR, in combination with clarithromycin and either amoxicillin or metronidazole, is indicated for the treatment of patients with peptic ulcer disease associated with Helicobacter pylori infection.
, asymptomatic) remains to be determined. The issue of whether or not eradication of H. pylori in patients with NSAID-associated ulcers might have beneficial preventive effects has not yet been settled. In dyspeptic patients with an H.
pylori infection, the concurrent gastritis can be healed with appropriate eradication therapy. 1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness.
Drug interactions
Known interactions involving Omeprazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL140170042 · revised May 29, 2026
- [2]FDA DailyMed · 0521c51b-d113-7e… · revised April 17, 2026 [PDF]
- [3]Health Canada (DPD) · 02420198 · revised May 13, 2026
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.